Melanoma News and Research

Latest Melanoma News and Research

Patients with MS appear to have reduced risk of cancer

Multiple sclerosis (MS) patients appear to have a lower cancer risk, according to a new study led by researchers at the University of British Columbia and Vancouver Coastal Health.

22 Jun 2012

Zebrafish provides insight into human melanoma

A transparent member of the minnow family is providing researchers at Weill Cornell Medical College in New York City with insight into human melanoma - a form of skin cancer - that may lead to new or repurposed drug treatments, for skin and other cancers.

19 Jun 2012

Delcath includes second-generation hemofiltration cartridge in chemosaturation system EAP

Delcath Systems, Inc. today announced that the Company has amended its Investigational New Drug (IND) application and its Expanded Access Program (EAP) to include the use of the second-generation hemofiltration cartridge of the Company's proprietary chemosaturation system.

19 Jun 2012

Skin cancer does not discriminate between skin colors

Do you have darker skin? If so, skin cancer might not be top of mind as a significant health threat, but beware – just because your skin is darker does not mean you are immune to skin cancer.

15 Jun 2012

Antibody that blocks programmed cell death benefits cancer patients

A national research collaboration of senior researchers, including a researcher from Moffitt Cancer Center, has found that 20 to 25 percent of "heavily pre-treated" patients with a variety of cancers who enrolled in a clinical trial had "objective and durable" responses to a treatment with BMS-936558, an antibody that specifically blocks programmed cell death 1 (PD-1).

14 Jun 2012

Azaya announces final results from ATI-1123 Phase I study on cancers

Azaya Therapeutics, Inc. announced final results from the Phase I study of its anti-cancer drug, ATI-1123 (liposomal docetaxel), today.

14 Jun 2012

Scientists decipher and block a molecular message that prompts unbridled cellular growth

What's good news in one setting might spell disaster in another. In cancer for instance, when a certain cell is commanded to grow and divide without restraint, it's a welcome message for the cell itself but a tragedy for the person who harbors this cell in his or her body. Weizmann Institute scientists have managed to decipher and block one type of molecular message that prompts unbridled cellular growth.

13 Jun 2012

Vitamin D deficiency may account for unexplained disparities in cancer survival rates

A paper just published in Dermato-Endocrinology suggests that vitamin D deficiency may account for unexplained disparities in cancer survival rates between African and White Americans.

10 Jun 2012

UF Proton Therapy Institute successfully treats first eye cancer patient

The fixed beam room, or eyeline, at the University of Florida Proton Therapy Institute is up and running and radiation oncologist Robert Malyapa, M.D., Ph.D. completed treating the facility's first eye cancer patient this week.

10 Jun 2012

Promising results for dabrafenib in advanced melanoma

The BRAF inhibitor dabrafenib shows promising results for treatment of advanced melanoma, both alone and in combination with the MEK inhibitor trametinib, show results from two studies presented at the American Society of Clinical Oncology Annual Meeting in Chicago, Illinois, USA.

8 Jun 2012

Vitamin A supplements may reduce skin cancer risk

Taking vitamin A supplements reduces the risk for developing a deadly form of skin cancer called melanoma, say US researchers.

8 Jun 2012

Erivedge drug shows promise against advanced basal cell carcinoma

It's the most common form of skin cancer, but in its advanced stages, basal cell carcinoma has the potential to become disfiguring and life threatening. An international phase 2 study headed by Mayo Clinic led to the recent Food and Drug Administration approval of the first drug of its kind to help advanced basal cell carcinoma patients who have few treatment options.

8 Jun 2012

VGXI, OncoSec partner to produce interleukin-12 plasmid DNA

OncoSec Medical Inc., which is developing its advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumors, announced today that the Company has entered into an exclusive cGMP manufacturing agreement with VGXI Inc. (VGXI) for the production of interleukin-12 plasmid DNA.

6 Jun 2012

New PD-1 blocking antibody shows promise against advanced kidney cancer

An antibody that helps a person's own immune system battle cancer cells shows increasing promise in reducing tumors in patients with advanced kidney cancer, according to researchers at Beth Israel Deaconess Medical Center.

5 Jun 2012

Jennerex announces data from JX-594 clinical studies on cancer

Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic virus products for cancer, today announced that data relating to the company's oncolytic virus therapy for cancer was featured in three separate abstracts during the American Society of Clinical Oncology (ASCO) Annual Meeting currently taking place in Chicago, Illinois.

5 Jun 2012

Promising data from Array BioPharma’s MEK162 Phase 2 trial on BRAF and NRAS mutant melanoma

Promising data on MEK162 in an ongoing Phase 2 trial of patients with BRAF and NRAS mutated advanced melanoma was presented today at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.

5 Jun 2012

Preliminary results from Incyte’s INCB024360 Phase I trial on solid tumors

Incyte Corporation presented preliminary results today from the ongoing Phase I clinical trial for its oral indoleamine dioxygenase-1 (IDO1) inhibitor, INCB024360, at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

5 Jun 2012

Antisense Pharma presents data from trabedersen Phase I/II cancer study at ASCO 2012

The biopharmaceutical company Antisense Pharma today presents trabedersen complete data from its clinical Phase I/II study in patients with advanced pancreatic cancer, malignant melanoma or colorectal cancer at the international cancer congress ASCO 2012 in Chicago, USA.

5 Jun 2012

Polynoma initiates POL 103A Phase III trial in melanoma

Polynoma LLC, a U.S. oncology-focused biopharmaceutical company within Hong Kong-based CK Life Sciences Int'l., today announced the start of a Phase III clinical trial program for POL 103A, the Company's novel melanoma vaccine. Polynoma's global, multi-center, double-blind, placebo-controlled Melanoma Antigen Vaccine Immunotherapy Study (MAVIS) is designed to enroll a total of 1059 patients with resected Stage IIb, IIc or III melanoma.

4 Jun 2012

Oncothyreon announces data from two clinical trials of PX-866 at ASCO meeting

Oncothyreon Inc. today announced that data from two clinical trials of PX-866, a pan-isoform phosphatidylinositol-3-kinase (PI-3K) inhibitor, were presented today at the American Society of Clinical Oncology (ASCO) meeting in Chicago.

4 Jun 2012